GEM-GLP1RA

Not yet recruitingPhase 4

Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery

Preoperative Metoclopramide to Enhance Gastric Emptying in Patients on Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Randomised Controlled Trial With Ultrasound Assessment

Lead sponsor

Mater Misericordiae University Hospital

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

—

Enrollment

estimated

Study population

Obesity / overweight, Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Presence of residual gastric content on preoperative gastric ultrasound

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07100691

Org study IDGEM-GLP1RA

Timeline

Milestones

Study first posted2025-08-03actual

Last update posted2025-08-06actual

Study start2025-08estimated (month precision)

Primary completion2026-05estimated (month precision)

Study completion2026-06estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweightPerioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients taking GLP-1 receptor agonists (for weight loss only)

•Male and female patients aged 18 years or older

•Able to provide written informed consent

•ASA grade I-V

•Scheduled for elective surgery with an expected overnight hospital stay

Exclusion criteria

•Inability to provide informed consent

•Presence of hiatus hernia

•History of any gastric surgery

•Pregnancy

•Inability to lie in the right lateral decubitus position

•Patients taking chronic opioids

•Poorly controlled diabetes (HbA1c >69 mmol/mol)

•Urgent or emergency surgery, including trauma

•Diagnosis of Parkinson's disease

•Allergy or intolerance to metoclopramide

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Other clinical outcomes

Safety / tolerability / PK

5 endpoints

Secondary/protocol endpoint

Nausea/vomiting in PACU

Time frame:2 hours

Nausea

descriptive, event

componentsNausea, Vomiting

Secondary/protocol endpoint

Nausea/vomiting

Time frame:24 hours

Vomiting

descriptive, event

componentsNausea, Vomiting

Secondary/protocol endpoint

Constipation

Time frame:24 hours

descriptive, event

Secondary/protocol endpoint

Adverse Reactions to Metoclopramide

Time frame:From enrollment to postoperative day 1.

descriptive, event

Secondary/protocol endpoint

Aspiration event

Time frame:From the induction of anaesthesia to post-operative 6 hours

event count, event

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

Presence of residual gastric content on preoperative gastric ultrasound

Time frame:On the day of surgery prior to anaesthesia induction

categorical status, event

Publications (10)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association.
Anaesthesia2025 Apr (month)PMID39781571doi:10.1111/anae.16541via CT.gov background
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia.
JAMA surgery2024 Jun 1PMID38446466doi:10.1001/jamasurg.2024.0111via CT.gov background
Glucagon-like peptide-1 receptor agonists in the perioperative period: Implications for the anaesthesiologist.
European journal of anaesthesiology2024 Mar 1PMID38298102doi:10.1097/EJA.0000000000001914via CT.gov background
ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.
Anesthesiology2024 Feb 1PMID37982170doi:10.1097/ALN.0000000000004776via CT.gov background
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
BMJ (Clinical research ed.)2024 Jan 29PMID38286487doi:10.1136/bmj-2023-076410via CT.gov background
Anesthetic Considerations in Adult Patients on Glucagon-Like Peptide-1 Receptor Agonists: Gastrointestinal Focus.
Anesthesia and analgesia2024 Jan 1PMID37874648doi:10.1213/ANE.0000000000006810via CT.gov background
Ultrasonic evaluation of metoclopramide's effect on gastric motility in emergency trauma patients.
Frontiers in physiology2023 (year)PMID37234409doi:10.3389/fphys.2023.999736via CT.gov background
Metoclopramide for the treatment of diabetic gastroparesis.
Expert review of gastroenterology & hepatology2019 Aug (month)PMID31314613doi:10.1080/17474124.2019.1645594via CT.gov background
Major complications of airway management in the UK: results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult Airway Society. Part 2: intensive care and emergency departments.
British journal of anaesthesia2011 May (month)PMID21447489doi:10.1093/bja/aer059via CT.gov background
Editorial II: Who is at increased risk of pulmonary aspiration?
British journal of anaesthesia2004 Oct (month)PMID15361474doi:10.1093/bja/aeh234via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.